OALib Journal期刊
腹腔灌注联合静脉化疗治疗晚期卵巢癌疗效观察 Clinical Effect of Intraperitoneal and Intravenous Chemotherapy for Advanced Ovarian Cancer
Keywords: 卵巢癌 ,顺铂 ,腹腔灌注 ,多西紫杉醇
Abstract:
目的:探讨顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌患者的疗效和不良反应。方法:选取晚期卵巢癌患者(Ⅲ-Ⅳ期)70例为研究对象,将患者随机分为顺铂联合多西他赛静脉化疗36例(对照组),以及顺铂腹腔灌注联合多西他赛静脉化疗34例(观察组)。对比分析两组化疗效果以及化疗不良反应。结果:观察组患者总有效率为76.47%,对照组总有效率为50.00%,两组比较差异有统计学意义(P<0.05)。观察组不良反应率为47.06%,毒副反应级别主要为Ⅰ-Ⅱ级。观察组与对照组相比,差异有统计学意义(P<0.05)。各组患者5年生存率无统计学意义(P>0.05);而观察组患者3年生存率为55.88%,显著高于对照组,差异有统计学意义(P<0.05)。观察组平均中位生存时间显著优于对照组,差异有统计学意义(P<0.05)。结论:顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌,较顺铂联合多西他赛静脉化疗疗效好,化疗毒副反应小
References
[1] Bristow RE.Predicting surgical cute for advanced ovarian cancer,surgical standards of care,and the concept of Kaizen[J].Gynecol Oncol,2009,112(1):1-3. [2] 何际平.腹腔加静脉化疗治疗晚期卵巢癌近期疗效观察[J].南华大学学报:医学版,2010,38(1):120-122. [3] Bristow RE,Giuntoli RL 2nd,Pannu HK.Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes[J].Gynecologic Oncology,2005,99(2):294-300. [4] 王星,李学东,陈聪.静脉化疗联合腹腔灌注化疗治疗晚期胃癌29例[J].肿瘤研究与临床,2011,10(3):632. [5] 李斌,刘丽影,章文华,等.泰索帝治疗晚期复发性卵巢癌研究现状[J].肿瘤防治杂志,2000,7(1):80-82. [6] Pignata S,Breda E,Scambia G.A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer(MITO-5)study[J].Crit Rev Oncol Hematol,2008,66(2):229-236. [7] 宋坤,孔北华.卵巢癌腹腔化疗的有关问题[J].现代妇产科进展,2010,19(10):721-724.
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
